Blog | ryans-quest

$1 Million in Funding Available to Drive Therapies for Duchenne Muscular Dystrophy

HAMILTON, N.J. and STATEN ISLAND, N.Y., Aug. 21, 2018 /PRNewswire-iReach/ -- Several gene therapies for Duchenne muscular dystrophy have advanced to clinical trials in recent months, offering great hope to the patient community. However, progress has been mired by manufacturing and safety setbacks, which resulted in clinical holds for two of the companies. Sadly, older patients are excluded from the initial series of gene therapy clinical trials, in part because they generall

Families of Boys with Duchenne Muscular Dystrophy Band Together to Fund Research

BALTIMORE, MD – (April 12, 2017) Three grassroots foundations founded by the families of young boys diagnosed with Duchenne muscular dystrophy (DMD) have jointly awarded a $100,000 grant to Kennedy Krieger Institute's Center for Genetic Muscle Disorders for research into novel drug therapies. The funding from Ryan's Quest, of New Jersey, along with Michael's Cause and Pietro's Fight, both of New York, will enable the scientific team to study existing drugs that have shown ea

DMD Therapeutics Inc. Receives Funding from DMD Foundations to Develop DMD-813 for Treatment of Duch

SEATTLE, Feb. 24 2017 /PRNewswire/ -- DMD Therapeutics, Inc., a start-up biotech company, is developing proprietary therapeutics for Duchenne muscular dystrophy (DMD), an orphan disease associated with serious morbidity and early mortality that has a major unmet need. The Company's first drug candidate, DMD-813, has been shown to reduce damage and inflammation in muscle leading to markedly increased muscle strength in the standard mouse model of DMD (mdx mice). Further studie

Two Nonprofit Organizations Award Iowa State University $150,000 for Muscular Dystrophy Research

Two Nonprofit Organizations Award Iowa State University $150,000 for Muscular Dystrophy Research

AMES, Iowa — Ryan’s Quest and Michael’s Cause, two nonprofit organizations, have provided a $150,000 grant to Iowa State University to study a combination of compounds that could be an effective therapy for children suffering from Duchenne muscular dystrophy. Ryan's Quest, based in New Jersey, and Michael’s Cause, based in New York City, are dedicated to finding treatments and a cure for Duchenne muscular dystrophy. The organizations’ funding will support the research of Josh

Michael's Cause, Ryan's Quest, Save Our Sons, Pietro's Fight, and Foundation LaForce Pro

Michael's Cause, Ryan's Quest, Save Our Sons, Pietro's Fight, and Foundation LaForce Pro

HAMILTON, N.J., March 24, 2016 /PRNewswire-iReach/ -- Ryan's Quest, a New Jersey based non-profit organization dedicated to finding treatments and a cure for Duchenne muscular dystrophy (DMD) is thrilled to announce the collaboration of five global Duchenne foundations to provide a $596,700 research grant to fund a promising Duchenne research project for Jerome Frenette Ph.D at The University of Laval in Quebec, Canada. Michael's Cause (USA), Pietro's Fight (USA), Save Our So

The Jett Foundation, Michael’s Cause and Ryan’s Quest Donate $15,000 to Scientific Committee Reviewi

The Jett Foundation, Michael’s Cause and Ryan’s Quest Donate $15,000 to Scientific Committee Reviewi

Dec.4, 2015 — Three Duchenne muscular dystrophy nonprofits have donated $5,000 each to TREAT-NMD Advisory Committee for Therapeutics (TACT), an international expert multidisciplinary body that provides objective guidance to clinicians, researchers, patient advocacy groups and industry on advancing new therapies for neuromuscular diseases. The Jett Foundation, Michael’s Cause and Ryan’s Quest, nonprofits created by families of boys and young men with Duchenne, believe that th

Ryan’s Quest Clinical Trial Grant for Steroid Alternative

Hamilton, New Jersey, August 3, 2015—The Ryan’s Quest Foundation, a non-profit organization specific to Duchenne muscular dystrophy, announced today the award of their most recent contribution toward the fight to end Duchenne muscular dystrophy. The Foundation has awarded ReveraGen BioPharma $50,000 towards a clinical trial for a potential steroid alternative. The grant was facilitated through a newly formed partnership of Duchenne Foundations, the Duchenne Alliance. VBP15 (V

NEWS: Akashi Therapeutics Reports Positive Clinical Data on HT-100 in Patients with Duchenne Muscula

NEWS: Akashi Therapeutics Reports Positive Clinical Data on HT-100 in Patients with Duchenne Muscula

Interim Clinical Data from Ongoing Phase 1b/2a Clinical Program Highlights Statistically Significant Improvements in Muscle Strength Cambridge, Mass. - June 18 , 2015 - Akashi Therapeutics Inc., a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy (DMD), today announced positive interim clinical data from an ongoing Phase 1b/2a clinical program with HT-100 (delayed-release halofuginone) an orally available, small molecule developed

NEWS: First Duchenne Muscular Dystrophy Patient Treated in Follistatin Gene Therapy Trial

Cleveland and Columbus, OH, April 9, 2015—Milo Biotechnology announced the first Duchenne muscular dystrophy (DMD) patient was treated with follistatin gene therapy at Nationwide Children’s Hospital. The therapy, delivered by intramuscular injection, is designed to maintain or restore muscle function in boys affected with DMD. This six patient clinical trial follows from a trial of the therapy in Becker muscular dystrophy patients that demonstrated initial safety and efficacy

Recent Posts

Search By Tags

No tags yet.